Allergan plc announces that, as expected, Allergan and AbbVie have each received a Request for Additional Information and Documentary Material (Second Request) from the US Federal Trade Commission (FTC) in connection with AbbVie’s pending acquisition of Allergan.

The Second Request was issued under notification requirements of the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended. The Second Request extends the waiting period under the HSR Act until 30 days after both Allergan and AbbVie have substantially complied with the Second Request.

Allergan and AbbVie are cooperating fully with the FTC and continue to expect to close the transaction in early 2020.

Completion of the acquisition, which was announced on June 25, 2019, remains subject to the approval of Allergan shareholders and satisfaction of other customary closing conditions, including expiration or termination of the waiting period under the HSR Act. Allergan has scheduled two special shareholder meetings on October 14, 2019 to seek the approval of its shareholders.

[Source(s): Allergan plc, PR Newswire]